IPP Bureau
Zydus and Synthon ink licensing and supply agreement for Ozanimod Capsules for US market
By IPP Bureau - September 05, 2025
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Edwards Lifesciences launches next-gen transcatheter heart valve in India
By IPP Bureau - September 05, 2025
Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology
FDA completes inspection at Biocon Biologics' facility in Bengaluru
By IPP Bureau - September 05, 2025
The U.S. FDA issued a Form 483 with five observations
AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
By IPP Bureau - September 05, 2025
The medicine was well tolerated, with no unexpected safety issue
CapVest to acquire majority stake in STADA
By IPP Bureau - September 05, 2025
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease
By IPP Bureau - September 05, 2025
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Quotient Sciences and CPI join forces to accelerate RNA drug development
By IPP Bureau - September 05, 2025
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
FDA expands medtronic MiniMed 780G system
By IPP Bureau - September 05, 2025
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Lupin receives FDA approval for Risperidone LAI with 180-day CGT exclusivity
By IPP Bureau - September 04, 2025
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Aarti Pharmalabs inaugurates phase 1 of greenfield manufacturing facility
By IPP Bureau - September 04, 2025
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
Caplin Steriles granted final approval for ANDA Milrinone Lactate in 5% Dextrose Injection by USFDA
By IPP Bureau - September 04, 2025
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
Cupid’s B2B export order book stands at Rs. 100 Cr+
By IPP Bureau - September 04, 2025
These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI
Syntegon reports H1 2025 EBITDA higher by 41% to €127 million
By IPP Bureau - September 04, 2025
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Brenntag Specialties selected European distributor for Kerry’s pharmaceutical-grade acetates
By IPP Bureau - September 04, 2025
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
